DSOL (Drug Free Solution) Debt-to-Equity: 0.00 (As of Feb. 2014)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Drug Free Solution Debt-to-Equity?

Drug Free Solution DSOL +100.00% Debt-to-Equity is 0.00 as of Feb. 2014.

Drug Free Solution's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2014 was $0.00 Mil. Drug Free Solution's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2014 was $0.00 Mil. Drug Free Solution's Total Stockholders Equity for the quarter that ended in Feb. 2014 was $-0.34 Mil. Drug Free Solution's debt to equity for the quarter that ended in Feb. 2014 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Drug Free Solution's Debt-to-Equity or its related term are showing as below:

DSOL's Debt-to-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.4
* Ranked among companies with meaningful Debt-to-Equity only.

Drug Free Solution  (OTCPK:DSOL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Drug Free Solution Debt-to-Equity Related Terms

Drug Free Solution Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Drug Free Solution's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drug Free Solution Debt-to-Equity Chart

Drug Free Solution Annual Data
Trend May12 May13
Debt-to-Equity
0.00 0.00

Drug Free Solution Quarterly Data
Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DSOL vs USEL, ZZLL, WSCO: Debt-to-Equity Comparison

For the Health Information Services subindustry, Drug Free Solution's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Drug Free Solution Debt-to-Equity vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Drug Free Solution's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Drug Free Solution's Debt-to-Equity falls into.


Drug Free Solution Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Drug Free Solution's Debt to Equity Ratio for the fiscal year that ended in May. 2013 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -0.051
=0.00

Drug Free Solution's Debt to Equity Ratio for the quarter that ended in Feb. 2014 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -0.339
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Drug Free Solution (DSOL) has a Debt-to-Equity of 0.00 as of Feb. 2014. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Drug Free Solution and its competitors.
Is Drug Free Solution's Debt-to-Equity too high?
Drug Free Solution's current Debt-to-Equity is 0.00.
How does Drug Free Solution's Debt-to-Equity compare to USEL and ZZLL?
Drug Free Solution's Debt-to-Equity of 0.00 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-Equity is 0.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.40, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Drug Free Solution and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drug Free Solution's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drug Free Solution stock overvalued right now?
Drug Free Solution (DSOL) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Drug Free Solution (DSOL), the current Debt-to-Equity is 0.00 as of Feb. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drug Free Solution Business Description

Address 2211 Michelson Drive, Irvine, CA, USA, 92612
Drug Free Solution Inc is a United States based holding company that owns and operates various subsidiaries in the healthcare industry. It is focused on acquiring healthcare operations that focus on Home Healthcare, Developmental Disabilities, Hospice Care, Skilled Nursing, Residential Rehabilitation, Home & Community Based Services.